Articles

Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term...

Editor’s note: Dr. Samady is an associate professor of medicine, division of cardiology,
Emory University School of Medicine, Atlanta. He wrote the following commentary on his...

Fractional flow reserve (FFR) is starting to change cardiologists’ minds about how to treat patients since the release of two-year results from the FAME (FFR vs. Angiography in Multivessel...

In recent years, the U.S. cardiac device market has focused on dynamics in the drug-eluting stent (DES) segment – including events ranging from the 2006 BASKET-LATE trial that caused a tremendous...

Standard drug-eluting stent technology seemed to have taken a backseat at this year’s TCT as cardiologists look forward to the next-generation DES using bioresorbable polymer coatings and totally...

September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT IV trial, which showed Abbott's XIENCE V Everolimus-Eluting Coronary Stent...

When vessels are stretched and ripped via angioplasty balloon expansion, the exposed soft muscle tissue can lead to the proliferation of scar tissue (neointimal hyperplasia) that can reocclude the...

Bare metal stents (BMS) were introduced in 1994 as an improvement over balloon angioplasty alone, which had a high restenosis rate of between 30-40 percent. The cobalt-chromium or stainless steel...

Stenting of lesions at coronary vessel bifurcations is one of the most challenging percutaneous interventions, along with a high risk of procedural complications and restenosis. Several companies...

Over the past year several new drug-eluting stents (DES) stents have been released and SYNTAX trial data proved DES compare as well as coronary artery bypass graft surgery (CABG) in patient...